NASDAQ Small-Caps in Focus: SNYR, RXT, CDIO, HTLM, KOS – Value Plays Gaining MomentumAs investors search for “top NASDAQ growth stocks 2026,” “small-cap breakout stocks,” and “functional beverage market growth,” several emerging names are gaining traction across financial platforms.
BioMedNewsBreaks — Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Schedules Investor Conference Call for Feb. 19, 2026Cardio Diagnostics Holdings (
NASDAQ: CDIO) announced it will host an investor conference call on Feb. 19, 2026, at 3 p.m. Central Time to provide an overview of its precision molecular approach to cardiovascular disease prevention and early detection. The call will include updates on the company commercially available tests, Epi+Gen CHD(TM) and PrecisionCHD(TM), as well as discussion of recent clinical data, reimbursement progress and strategic growth initiatives.
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, February 19, 2026
Please replace the release dated February 17, 2026 with the following corrected version due to multiple revisions.
Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India
Cardio Diagnostics Holdings, Inc. (
NASDAQ: CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories and 300+ MD pathologists in their internal network, today announced a strategic agreement to launch Cardio Diagnostics’ PrecisionCHD™ test for the detection and management of coronary heart disease (CHD) in India.
Cardio Diagnostics Holdings, Inc. and Southdale YMCA Announce New Heart Health Partnership to Serve the Edina, Minnesota Community
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced a new partnership with the Southdale YMCA to bring expanded heart health education and advanced cardiovascular testing to their members and the broader Edina community. The Southdale YMCA primarily serves the Edina, Richfield, Bloomington, and South Minneapolis areas, supporting more than 14,000 individuals, approximately 80% of whom are adults.
Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests. This finalized rate represents an increase from the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. Obtaining the final rate represents a positive development and will be effective for claims with dates of service on or after January 1, 2026.
Cardio Diagnostics Holdings, Inc. to Present Data Demonstrating PrecisionCHD’s Ability to Detect INOCA and MINOCA at the American Heart Association Scientific Sessions
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered Precision Cardiovascular Medicine company, today announced that the Company will be presenting new data at the American Heart Association (AHA) Scientific Sessions demonstrating that the epigenetic biomarkers of the Company’s PrecisionCHD test are able to detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) presentations. PrecisionCHD is an integrated epigenetic-genetic blood test that aids in the diagnosis of coronary heart disease (CHD). The AHA Scientific Sessions will take place in New Orleans, LA, from November 7 to 10.
Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Company is partnering with YMCA of East Tennessee to launch a customized program exclusively for its members. Through this program, YMCA members will learn how to take proactive steps to prevent and detect heart disease early while gaining access to Epi+Gen CHD™ and PrecisionCHD™ clinical tests from Cardio Diagnostics at a special discounted rate.
Cardio Diagnostics Holdings, Inc. Expands Provider Network, Adding 15 New Provider Organizations From Across the United States
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven Precision Cardiovascular Medicine company, today announced the Company has partnered with 15 new provider organizations across the United States. This expansion demonstrates the continued adoption of the Company's innovative blood tests, Epi+Gen CHD™ and PrecisionCHD™, which are transforming the prevention, detection, and management of coronary heart disease across diverse clinical settings.
Cardio Diagnostics Receives Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS), through the MolDX program, has issued preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. A ‘gapfill’ payment rate means that pricing is determined by each Medicare contractor, including MolDX, based on cost data from Cardio Diagnostics.
Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease
Cardio Diagnostics Holdings Inc. (
NASDAQ: CDIO), a precision cardiovascular medicine company with a pioneering technology at the intersection of epigenetics and AI, today announced an agreement with AGEPHA Pharma that will enable the validation of a precision-guided approach to treating inflammation-driven coronary heart disease (CHD). Specifically, AGEPHA Pharma will supply LODOCO® (low-dose colchicine), its FDA-approved anti-inflammatory medication, for a Cardio Diagnostics-sponsored clinical study to explore the use of Cardio Diagnostics’ PrecisionCHD™ blood test to identify patients with inflammation-driven coronary heart disease (CHD) and assess their response to LODOCO® over time.
Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology
Cardio Diagnostics Holdings Inc. (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company’s intellectual property portfolio. The patent, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease,” (Japanese Patent No. 7672192) is exclusively licensed to Cardio Diagnostics from the University of Iowa Research Foundation (UIRF) and names Cardio Diagnostics’ founders Meesha Dogan, Ph.D., Chief Executive Officer, and Robert Philibert, MD, Ph.D., Chief Medical Officer, as inventors.
Cardio Diagnostics Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a pioneer in AI-powered precision cardiovascular medicine, today announced that on May 28, 2025, it received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Requirement”) for continued listing on The Nasdaq Capital Market. This was disclosed in the Company’s Current Report on Form 8-K filed on May 28, 2025.
